AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing GlioblastomaKevin J. Hamblett, William C. Fanslow, Esther S. Trueblood et al.|Molecular Cancer Therapeutics|2015Cited by 99
Visceral fat: A key mediator of NAFLD development and progressionSavita Bansal, Archana Burman, Meenakshi Vachher et al.|Human Nutrition & Metabolism|2023Cited by 58
Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinomaMeenakshi Vachher, Archana Burman, Nalini Moza Wali et al.|Journal of Cellular Biochemistry|2022Cited by 11